Stocks · News reference
PolyPid Signs Agreement With Azurity Pharmaceuticals To Commercialize D-PLEX100 In U.S., Canada To Prevent Surgical Site Infections; PolyPid To Receive $15M Upfront Payment
PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins, today announced that it has
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
PolyPid Q2 EPS $(0.35) Beats $(0.38) Estimate
PolyPid (NASDAQ:PYPD) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.38) by 7.89 percent. This is a 55.13 percent increase over losses of $(0.78) per share from the same
PolyPid shares are trading higher after the company announced that the FDA accepted its New Drug Application and granted it a Priority Review for D-PLEX100
PolyPid Announces FDA Acceptance Of Its New Drug Application With A Priority Review For D-PLEX100 For The Prevention Of Surgical Site Infections In Patients Undergoing Abdominal Colorectal Surgery; PDUFA Action Date Is November 28